SELLAS Life Sciences (SLS) Long-Term Debt Repayments (2010 - 2018)
SELLAS Life Sciences (SLS) reported Long-Term Debt Repayments of $76000.0 for Q4 2018, down 36.67% year-over-year from $120000.0 in Q4 2017, and down 98.9% quarter-over-quarter from $6.9 million in Q3 2018.
SELLAS Life Sciences (SLS) Long-Term Debt Repayments (2010 - 2018) Analysis & Trends
SELLAS Life Sciences (SLS) has 9 years of Long-Term Debt Repayments data on file, last reported at $76000.0 in Q4 2018.
- Long-Term Debt Repayments for Q4 2018 came in at $76000.0, down 36.67% year-over-year; the trailing twelve-month figure through Sep 2019 was $76000.0 (down 99.01% YoY), and the FY2018 annual result was $7.6 million, up 1506.98% from the prior year.
- Long-Term Debt Repayments retreated to $76000.0 in Q4 2018 per SLS's latest filing, from $6.9 million in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $6.9 million in Q3 2018 and troughed at $1000.0 in Q3 2017.
- A 5-year average of $1.1 million and a median of $858000.0 in 2014 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2017 and 2018: Long-Term Debt Repayments tumbled 90.61% in 2017, then soared 693500.0% in 2018.
- A 5-year view of Long-Term Debt Repayments shows it stood at $858000.0 in 2014, then grew by 17.6% to $1.0 million in 2015, then dropped by 20.71% to $800000.0 in 2016, then tumbled by 85.0% to $120000.0 in 2017, then plunged by 36.67% to $76000.0 in 2018.
- Business Quant data shows SLS's Long-Term Debt Repayments at $76000.0 in Q4 2018, $6.9 million in Q3 2018, and $589000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 76,000.00 |
| Dec 31, 2018 | 76,000.00 |
| Sep 30, 2018 | 6.94 Mn |
| Sep 30, 2018 | 6.94 Mn |
| Mar 31, 2018 | 589,000.00 |
| Mar 31, 2018 | 589,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Dec 31, 2017 | 120,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 352,000.00 |
| Jun 30, 2017 | 352,000.00 |
| Dec 31, 2016 | 800,000.00 |
| Dec 31, 2016 | 800,000.00 |
| Jun 30, 2016 | 3.75 Mn |
| Jun 30, 2016 | 3.75 Mn |
| Mar 31, 2016 | 1.03 Mn |
| Mar 31, 2016 | 1.03 Mn |
| Dec 31, 2015 | 1.01 Mn |
| Dec 31, 2015 | 1.01 Mn |